Test your risk
of breast cancer
1 in 8 women in Australia develop breast cancer during her lifetime1 – and most will have no significant family history. 2,3
That’s why geneType for Breast Cancer looks beyond family history.
Know your risk to learn more about your options to reduce that risk.
Most breast cancers are diagnosed
in women with no significant family history2,3
There are a variety of risk factors that may influence your overall risk of breast cancer including:¹
Personalized risk score. Personalized health plan.
GeneType for Breast Cancer can help you and your health provider develop a risk reduction health plan just for you.
Depending on your risk, your health provider may consider:
- Managing the risk factors you can change
- Additional breast screening that may include mammograms, ultrasound and/or MRI
- Risk-reducing medications (if appropriate)
- Consultation with a specialist
Uniquely powered to assess your risk
GeneType for Breast Cancer is the only test that gives you a comprehensive and highly accurate risk prediction score based on your:⁴
- Your own genetic markers of breast cancer risk
- Your age
- Your family history of breast cancer (if any)
- Your body mass index
- Your breast density from your last mammogram (if available)
- Your menopausal status
If you order geneType through your medical practitioner, you will receive your results directly from them.
Unlock the power of your DNA
By looking at common markers of risk in your genes, we get a better picture of disease risk. We call this risk factor, gene risk.
Everyone has these markers, but not everyone has the same combination. Like a fingerprint, your genetic markers are unique to you, and can help define your “baseline” risk of developing breast cancer.
What will my geneType for Breast Cancer results tell me?
Your results will tell you, based on genetics and other risk factors, your risk for developing sporadic breast cancer over two different time periods: in the next 5 years and in your remaining lifetime.
You and your healthcare provider can use this information to develop a personalized screening and risk reduction plan
If I already get my regular mammogram, do I still need to know my breast cancer risk score?
Great work maintaining your routine mammogram screening!
Your Breast Cancer risk score can also help you and your healthcare provider develop a personalized screening plan for you, which may involve additional screening than just mammogram alone.
If my risk of breast cancer is not elevated, can I skip my mammogram screenings?
Your geneType for Breast Cancer results will indicate whether you are at increased risk, or average risk. If you are at average risk, it is still important to follow the recommended screening guidelines for women of your age.
What do I do with my results?
If you ordered geneType through your own health provider, you will receive your results directly from them.
Will insurance cover this test?
This test is not generally covered by insurance. However, you may use FSA/HSA to pay for the test. Your ordering healthcare provider will discuss the cost of the test with you. A credit card authorization form will be included in the test kit that lists the payment options. Or you will be able to pay via the geneType patient portal.
Know your risk of breast cancer so you can take action
Interested in ordering more than one disease? Order geneType Multi-Test.
See individual disease pages for more information about each test.
The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for 8 diseases in the panel; a man would be eligible for 7. Starting at age 30, a patient may qualify for geneType's cancer risk assessments only.
*Patient eligibility dependent on personal medical history, age and sex
Under the fluorescent lights of a doctor’s office, it’s not always easy to know what questions to ask. Here are some breast cancer risk questions…
Breast awareness is important whether you are 35 or 75. When you understand your risk, you can be a better advocate for yourself…
Genetic Technologies changed a lot in the last year. Our product innovations, expansion into new therapy areas and acquisitions…
- American Cancer Society (2012). Accessed June 2022.
- van der Groep P et al. Cell Oncol (Dordr) 2011;34:71–88.
- Shiyanbola OO et al. Cancer Epidemiol Biomarkers Prev 2017;26:1753–60.
- Dite GS et al. Cancer Epidemiol Biomarkers Prev 2016;25:359–65.
Keep up-to-date with our latest advances
Sign up to our newsletter to stay informed about our latest advances and how these could support your practice.